Impacts of resistance training combined with vibration training on the IGF-1/PI3K/AKT/FOXO3 axis and clinical outcomes in patients with sarcopenia: A protocol for a randomized controlled trial

What Was Tested

This clinical study looks at IGF-1 LR3.

Sarcopenia is an age-associated disorder characterized by a progressive decline in skeletal muscle mass, strength, and physical function.

The condition is linked to low levels of anabolic hormones such as insulin-like growth factor 1 (IGF-1), with its downstream phosphatidylinositol 3 kinase (PI3K)/ protein kinase B (AKT)/ forkhead box protein O3 (FOXO3) signaling pathway.

Who Took Part

According to the abstract, 96 participants were involved.

The age groups tagged for this paper are older adults and people over 80, both men and women.

This prospective randomized controlled trial will be conducted among 96 participants, aged between 65 and 80 years.

In participants, sarcopenia diagnosis will be confirmed based on the Asian Working Group for Sarcopenia criteria, and participants will be randomized into either control, RT, VT, or RVT (combined RT and VT) groups.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.

The intervention will last 12 weeks, with assessments performed at baseline, 12 weeks (after intervention), and 24 weeks (follow-up).

The primary outcomes will include skeletal muscle mass, handgrip strength, and gait speed.

Secondary outcomes comprise IGF-1 concentrations, PI3K/AKT and FOXO3 protein activity, quality of life, and timed-up-and-go test performance assessments.

What Was Measured

The condition is linked to low levels of anabolic hormones such as insulin-like growth factor 1 (IGF-1), with its downstream phosphatidylinositol 3 kinase (PI3K)/ protein kinase B (AKT)/ forkhead box protein O3 (FOXO3) signaling pathway.

The subject headings attached to it are Sarcopenia, Resistance Training, Insulin-Like Growth Factor I, Forkhead Box Protein O3, Proto-Oncogene Proteins c-akt, Vibration and Signal Transduction.

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3 in 96 participants.

The abstract goes on to report its results in about 1 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (PloS one), a journal based in United States.

More context: the IGF-1 LR3 compound page, all human trials.